O'Reilly M S, Holmgren L, Shing Y, Chen C, Rosenthal R A, Moses M, Lane W S, Cao Y, Sage E H, Folkman J
Department of Surgery, Children's Hospital, Boston, Massachusetts.
Cell. 1994 Oct 21;79(2):315-28. doi: 10.1016/0092-8674(94)90200-3.
The phenomenon of inhibition of tumor growth by tumor mass has been repeatedly studied, but without elucidation of a satisfactory mechanism. In our animal model, a primary tumor inhibits its remote metastases. After tumor removal, metastases neovascularize and grow. When the primary tumor is present, metastatic growth is suppressed by a circulating angiogenesis inhibitor. Serum and urine from tumor-bearing mice, but not from controls, specifically inhibit endothelial cell proliferation. The activity copurifies with a 38 kDa plasminogen fragment that we have sequenced and named angiostatin. A corresponding fragment of human plasminogen has similar activity. Systemic administration of angiostatin, but not intact plasminogen, potently blocks neovascularization and growth of metastases. We here show that the inhibition of metastases by a primary mouse tumor is mediated, at least in part, by angiostatin.
肿瘤块对肿瘤生长的抑制现象已被反复研究,但尚未阐明令人满意的机制。在我们的动物模型中,原发性肿瘤会抑制其远处转移。肿瘤切除后,转移灶会形成新血管并生长。当原发性肿瘤存在时,转移灶的生长会被一种循环血管生成抑制剂所抑制。荷瘤小鼠的血清和尿液,而非对照小鼠的血清和尿液,能特异性抑制内皮细胞增殖。该活性与一个我们已测序并命名为血管抑素的38 kDa纤溶酶原片段共同纯化。人纤溶酶原的相应片段具有相似活性。全身性给予血管抑素而非完整的纤溶酶原,可有效阻断转移灶的新血管形成和生长。我们在此表明,原发性小鼠肿瘤对转移灶的抑制至少部分是由血管抑素介导的。